Ubidecarenone
C59 H90O4 863.37
2,5-Cyclohexadiene-1,4-dione, 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6- dimethoxy-3-methyl;2-[(all-E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38 tetracontadecaenyl)-5,6- dimethoxy-3-methyl-p-benzoquinone [303-98-0].
DEFINITION
Ubidecarenone (Coenzyme Q10) contains NLT 98.0% and NMT 101.0% of ubidecarenone (C59 H90O4), calculated on the anhydrous basis.
IDENTIFICATION
. A. INFRARED ABSORPTION〈197K〉
. B.
Analysis: Dissolve 50 mg of Ubidecarenone in 1 mL of ethyl ether, and add 10 mL of dehydrated alcohol. To 2 mL of this solution add 3 mL of dehydrated alcohol and 2 mL of dimethyl malonate. Add 1 mL of potassium hy- droxide solution (1 in 5) dropwise.
Acceptance criteria: A blue color appears.
IDENTIFICATION
. A. INFRARED ABSORPTION〈197K〉
. B.
Analysis: Dissolve 50 mg of Ubidecarenone in 1 mL of ethyl ether, and add 10 mL of dehydrated alcohol. To 2 mL of this solution add 3 mL of dehydrated alcohol and 2 mL of dimethyl malonate. Add 1 mL of potassium hy- droxide solution (1 in 5) dropwise.
Acceptance criteria: A blue color appears.
ASSAY
. PROCEDURE
Mobile phase: Methanol and dehydrated alcohol (65:35)
System suitability solution: 0.5 mg/mL each of USP Ubidecarenone RS and USP Ubidecarenone Related Com- pound A RS in dehydrated alcohol. Heat at 50。for 2 min, if necessary, for complete dissolution.
Standard solution: 1.0 mg/mL of USP Ubidecarenone RS in dehydrated alcohol. Heat at 50。for 2 min, if nec- essary, for complete dissolution.
Sample solution: 1.0 mg/mL of Ubidecarenone in dehy- drated alcohol. Heat at 50。for 2 min, if necessary, for complete dissolution.
Chromatographic system
(See Chromatography〈621〉, System Suitability.)
Mode: LC
Detector: UV 275 nm
Column: 4.6-mm × 15-cm; packing L1
Column temperature: 35。
Flow rate: Adjust to obtain a retention time of about 11 min for ubidecarenone.
Injection size: 5 µL
Get a Quote - COENZYME Q10 Powder
Hot Tags: UBIQUINONEQ10;,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-;2,5-cyclohexadiene-1,4-dione,2-(3,7,11,15,19,23,27,31,35,39-de
